Poor outcomes include lower response rate to chemotherapy, higher mortality, recurrence
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Smoking is tied to worse bladder cancer outcomes following radical cystectomy, according to a review published online Oct. 1 in The Journal of Urology.
Giovanni E. Cacciamani, M.D., from the University of Southern California in Los Angeles, and colleagues conducted a systematic literature search to identify studies evaluating tobacco smoking exposure, duration, intensity, and cessation on response to neoadjuvant chemotherapy and long-term survival outcomes in patients undergoing radical cystectomy for bladder cancer.
Based on 17 studies (13,777 patients), a pooled meta-analysis revealed that active smokers had an increased risk for overall mortality (hazard ratio [HR], 1.21), cancer-specific mortality (HR, 1.24), and bladder cancer recurrence (HR, 1.24). When analyzing only patients who underwent neoadjuvant chemotherapy followed by radical cystectomy, nonsmokers and never smokers showed an advantage in terms of neoadjuvant chemotherapy complete response rate compared with active smokers (HR, 0.47).
“Appropriate preoperative counseling, together with tightened follow-up, may have a pivotal role in improving the smoking-related long-term survival outcomes in patients with bladder cancer,” the authors write.
Prenatal Coexposure to Smoking, Alcohol Linked to Facial Dysmorphism 
Financial Incentives Boost Tobacco Abstinence in Underserved Adults 
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer 
ASTRO Issues Guidance for Use of Radiation Therapy in Bladder Cancer 
Guidelines Updated for Short-Course Radiation for Localized Prostate Cancer 
Early Survivorship Care Linked to Improved Outcomes in Head, Neck Cancer 
Recommendations Updated for Radiation Therapy in Pancreatic Cancer 
Thymic Radiation Linked to Worse Outcomes in Patients With NSCLC 
